Jeong Kim

NGM Biopharmaceuticals (United States) — United States

Immunology and Microbiology · Life Sciences

15h-index6.9kcitations46works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(23), Cancer Immunotherapy and Biomarkers(12), T-cell and B-cell Immunology(10), Immunotherapy and Immune Responses(10), Cancer Research and Treatments(10)

Publications46 total

Figure S2 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Table S4 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Table S5 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Figure S3 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Data from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Table S3 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Figure S3 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Table S3 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Table S2 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Table S1 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Table S4 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Figure S4 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Figure S1 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Figure S1 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Table S1 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Table S2 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Data from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Table S5 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Figure S2 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
Figure S4 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
2024Open Access
page 1 of 3Next →

Frequent Co-authors

Jonathan Sitrin(22), B. Leticia Rodriguez(21), Jiawei Huang(21), Laura Gibson(21), Jared J. Fradette(21), Hung-I Harry Chen(21), Kikuye Koyano(21), Czrina Cortez(21), Betty Li(21), Carmence Ho(21), Amir M. Ashique(21), Vicky Y. Lin(21), Suzanne Crawley(21), Julie M. Roda(21), Peirong Chen(21), Bin Fan(21), James Sissons(21), Daniel D. Kaplan(21), Don L. Gibbons(21), Lee B. Rivera(21)